

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/089,452	01/27/2003	Christian Reiter	42314	9277
35928	7590 11/03/2004	,	EXAM	INER
GRAY CARY WARE FREDENRICH 1625 MASSACHUSETTS AVENUE, NW SUITE 300 WASHINGTON, DC 20036-2247			MINNIFIELD, NITA M	
			ART UNIT	PAPER NUMBER
			1645	
	•		DATE MAILED: 11/03/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/089,452	REITER ET AL.				
Office Action Summary	Examiner	Art Unit				
	N. M. Minnifield	1645				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on						
2a) This action is FINAL . 2b) This	This action is FINAL . 2b) This action is non-final.					
• • • • • • • • • • • • • • • • • • • •	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) Claim(s) 1-54 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-54 are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal I 6) Other:					

Art Unit: 1645

DETAILED ACTION

1. Applicants' preliminary amendment filed September 22, 2004 is acknowledged and has been entered. Claims 5-7, 14-36, 38-42, 44, 45 and 49-53 have been amended. Claims 1-54 are pending in the present application.

Election/Restrictions

2. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-42, drawn to a method for detecting infection of a mammal with an acid-resistant microorganism.

Group II, claims 43-48, drawn to a monoclonal antibody, aptamer and epitope.

Group III, claims 49-52 and 54, drawn to a diagnostic composition, test device and kit.

Group IV, claim 53, drawn to a pharmaceutical composition.

Art Unit: 1645

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The technical feature of Group I, the method of detecting infection comprising the process as defined in claim 1, is not special in view of the method of detection and antibodies to *H. pylori* antigen disclosed in Larka et al 5932430, see claim 1 and column 2. The technical feature of Group I is not special in that it does not define a novel contribution over the prior art; as such there is not a special technical feature and therefore the Groups of inventions, I-IV, lack a corresponding special technical feature.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

- Group I a) elect one acid-resistant microorganism, see claims 3 and 4;
 - b) elect one antigen, catalase, urease, metalloproteinase, see claim 5;
 - c) if catalase is elected in b),

elect one group of sequences (aa and corresponding nt sequence) that define the heavy chain of the antibody binding a catalase epitope (CDR1, CDR2, CDR3, SEQ ID NO: 9-14, 21-26), see claims 15, 16, 19, 20

Art Unit: 1645

elect one group of sequences (aa and corresponding nt sequence) that define the light chain of the antibody binding a catalase eiptope (CDR1, CDR2, CDR3, SEQ ID NO: 15-20, 27-32), see claims 17, 18, 21, 22;

d) if β -urease is elected in b),

elect one group of sequences (aa and corresponding nt sequence) that define the heavy chain of the antibody binding an epitope of β -urease (CDR1, CDR2, CDR3, SEO ID NO: 33-44), see claims 23 and 24;

elect one group of sequences (aa and corresponding nt sequence) that define the light chain of the antibody binding an eiptope of β -urease (CDR1, CDR2, CDR3, SEQ ID NO: 45-56), see claims 25 and 26;

e) elect variable region for light chain and heavy chain, elect one sequence from SEQ ID NO: 1-8, see claims 27 and 28.

Group II elect one specific combination of CDRs for the V region, define the CDRS and corresponding sequence by SEQ ID NO, see claims 43 and 44.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by

Art Unit: 1645

37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner: see above.

The following claim(s) are generic: claim 1.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: Larka et al 5932460, disclose an antigen and antibody from *H. pylori*.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to N. M. Minnifield whose telephone number is 571-272-0860. The examiner can normally be reached on M-F (8:00-5:30) Second Friday Off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette R.F. Smith can be reached on 571-272-0864. The

Art Unit: 1645

fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Primary Examiner

Art Unit 1645

NMM

October 1, 2004